Inmagen secures licensing for Hutchmed’s drug candidates for immune and inflammatory ailments 

USA – Global biotech company focused on creating new treatments for immune and inflammatory diseases Inmagen, has decided to secure exclusive rights to two drug candidates from Hutchmed, known as IMG-007 and IMG-004. 

This agreement allows Inmagene to use and sublicense these drugs as part of a collaboration that started in 2021 to develop and sell a range of treatments in the field of immune and inflammatory diseases. 

Hutchmed, is an innovative, commercial-stage, biopharmaceutical company, that is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.  

It will be paid $92.5 million for reaching certain development milestones and an additional $135 million for commercial milestones for each drug candidate, aside from royalties based on sales. 

IMG-007 is a special kind of antibody designed to block a certain pathway in the body that contributes to immune and inflammatory responses. 

 It is currently being tested in Phase IIa trials for skin conditions like atopic dermatitis and alopecia areata. 

IMG-004, on the other hand, is a pill that targets inflammation and autoimmune diseases. Early studies suggest it has a long-lasting effect, potentially allowing for once-daily dosing. 

 It is currently being studied for conditions like chronic spontaneous urticaria and rheumatoid arthritis. 

In addition to these drugs, Inmagene is also developing its own drug, IMG-008, which is designed to target another pathway involved in immune and inflammatory diseases. 

Also read:

1: China NMPA greenlights clearance of Fermion’s TYK2 JH2 inhibitor

2: Novartis to acquire MorphoSys for US$2.9B to bolster oncology portfolio

Jonathan Wang, the CEO of Inmagene, expressed excitement about the partnership with Hutchmed, stating that obtaining exclusive rights to these promising drug candidates is a significant step towards becoming a leader in developing new treatments for immune and inflammatory diseases worldwide. 

“Obtaining the worldwide exclusive rights is another step forward in our journey to become a global leader in novel drug development for I&I diseases,” he said. 

For all the latest healthcare industry news from Africa and the World, subscribe to our NEWSLETTER, and YouTube Channel, follow us on Twitter and LinkedIn, and like us on Facebook.